Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Nat Commun. Author manuscript; available in PMC 2014 February 25.
Published in final edited form as:
PMCID: PMC3934748

Reductive glutamine metabolism is a function of the α-ketoglutarate to citrate ratio in cells


Reductively metabolized glutamine is a major cellular carbon source for fatty acid synthesis during hypoxia or when mitochondrial respiration is impaired. Yet, a mechanistic understanding of what determines reductive metabolism is missing. Here we identify several cellular conditions where the α-ketoglutarate/citrate ratio is changed due to altered acetyl-CoA to citrate conversion, and demonstrate that reductive glutamine metabolism is initiated in response to perturbations that results in an increase in the α-ketoglutarate/citrate ratio. Thus, targeting reductive glutamine conversion for a therapeutic benefit might require distinct modulations of metabolite concentrations rather than targeting the upstream signaling, which only indirectly affects the process.

Uncontrolled cell proliferation associated with cancer necessitates metabolic alterations to support rapid cell growth; hence understanding these changes is of critical importance in identifying new and promising cancer therapies1, 2. While substantial progress has been made in elucidating how altered signaling events promote uncontrolled proliferation in cancer, our knowledge regarding the metabolic rearrangements that provide building blocks for biomass, ATP, and generation of reducing equivalents remains limited3, 4. Recently, we and other groups identified reductively metabolized glutamine as the major carbon source of fatty acid synthesis during hypoxia and impaired respiration5, 6, 7, 8. Moreover, this switch in carbon source selection was shown to be of particular importance for sustaining rapid cell proliferation5, 7.

Both hypoxia and the loss of the Von-Hippel Lindau gene (VHL)9, 10 promote reductive glutamine metabolism, while inhibition of pyruvate dehydrogenase kinase isoform 1 (PDK1), a target of the VHL-hypoxia inducible factor (HIF1α) axis 11, 12, also decreases reductive glutamine utilization in various cell systems5, 7. Additionally, reductive glutamine utilization is activated during impaired respiration, thereby raising the possibility that alterations in NAD+/NADH metabolism might be involved6. However, a mechanistic understanding of how hypoxia, respiratory impairment, and expression changes in VHL and PDK1 all converge to impact reductive glutamine metabolism is lacking. As a result, the prediction of how other environmental, genetic, or pharmacological interventions might trigger reductive glutamine utilization is not possible.

In this study we aim to identify how the switch to reductive glutamine utilization is controlled in cells. To this end we systematically measure changes in metabolite levels and metabolic flux contributions in cancer cell lines following various cellular perturbations, and examine the impact of these changes on reductive glutamine metabolism. We find that reductive glutamine metabolism is a general phenomenon that occurs in response to any intervention that increases the α-ketoglutarate/citrate ratio. Specifically, changes in this ratio are predicted to increase reductive glutamine metabolism by mass action. Furthermore, in most conditions tested, a decrease in acetyl-CoA (AcCoA) to citrate conversion, triggered by one of at least two different mechanisms, is an event responsible for the alteration in the α-ketoglutarate/citrate ratio, suggesting this as a key node in determining reductive glutamine metabolism.


Oxidative and reductive glutamine metabolism

In mammalian cells glutamine can be an important contributor of carbon to the TCA cycle13, 14 where it can be metabolized in the oxidative or reductive direction5, 6. Reductive glutamine metabolism involves the conversion of α-ketoglutarate to citrate and acts as a carbon source to fuel fatty acid synthesis (Figure 1a). In oxidative glutamine metabolism, α-ketoglutarate is oxidized to succinate for the eventual conversion to citrate by the TCA cycle. Interconversion of citrate and isocitrate is necessary for the TCA cycle to operate in either direction; this reaction is often found close to equilibrium such that isocitrate is maintained at approximately 6.5% of the citrate concentration15. We experimentally validated the equilibrium assumption for the culture conditions and treatments tested here, and found the isocitrate concentration to be 4.1% ± 0.79% of the citrate concentration under standard culture condition and 5.3% ± 0.85% of the citrate concentration following metformin treatment. Therefore, to simplify our analysis we focused our measurements on citrate as the more abundant metabolite. Because α-ketoglutarate and citrate levels represent the substrate or product in key reactions of reductive versus oxidative glutamine metabolism, their levels are predicted to be critical parameters in determining the reaction direction. While both metabolites are present in the cytosol and the mitochondria we analyzed the total pool size due to the lack of established methods to quantitatively separate the two pools. Furthermore, we decided to specifically focus on the reductive glutamine contribution instead of the reductive net flux, because net fluxes per se are also a function of growth rate16. Because many of the perturbations used in this study influence cell growth, it is impossible to control for secondary effects on net flux resulting from changes in cell growth.

Figure 1
Reductive carboxylation correlates with concomitant metabolic parameters. (a) Reductive (α-ketoglutarate to citrate) versus oxidative (citrate to α-ketoglutarate) flux and concomitant network reactions and metabolites. Reductive glutamine ...

Reductive carboxylation is regulated on a metabolic level

To elucidate the mechanism responsible for the switch from oxidative to reductive glutamine utilization, we measured reductive glutamine contribution to citrate and changes in the levels of citrate and α-ketoglutarate using U-13C glutamine and gas chromatography - mass spectrometry5. We compared cells under conditions previously described to induce reductive glutamine metabolism: hypoxia, or treatment with rotenone, metformin, and antimycin a 5, 6, 7, 8. The respiratory chain inhibitors rotenone, metformin and antimycin a were all used at concentrations that cause an approximately 50% decrease in oxygen consumption (Supplementary Figure S1). As expected, reductive glutamine contribution to citrate (identified by the level of the M+5 mass isotopomer of citrate from U-13C glutamine (Supplementary Figure S2a)) increased for all conditions compared to the control condition (Figure 1b). Furthermore, the citrate and α-ketoglutarate levels decreased in all conditions; however, the decrease in citrate was much greater than the decrease in α-ketoglutarate (Figure 1c). Strikingly, the α-ketoglutarate/citrate ratio correlated with the magnitude of reductive glutamine contribution to citrate (Figure 1 b, c, e; Supplementary Data 1). This suggests that changes in the α-ketoglutarate/citrate ratio could be the principal driving force for the switch from oxidative glucose to reductive glutamine metabolism, promoting the use of glutamine as the primary carbon source for citrate synthesis. Because lipogenic AcCoA is derived from citrate5, this ratio might determine the source of carbon for lipid synthesis (Figure 1a).

The correlation between reductive glutamine contribution to citrate and increased α-ketoglutarate/citrate ratio raises the question of how this ratio is determined. Besides glutamine also glucose can contribute to citrate and α-ketoglutarate levels17. We inferred the latter flux contribution with a U-13C glucose tracer by measuring the total glucose contribution to citrate or the AcCoA contribution to α-ketoglutarate. Total glucose contribution to citrate, and AcCoA contribution to α-ketoglutarate (M+2 of α-ketoglutarate from U-13C glucose (Supplementary Figure S2b)), decreased in all conditions compared to control (Figure 1d). Moreover, the percent of M+2 α-ketoglutarate from U-13C glucose and the percent citrate labeling from glucose both correlated inversely with the reductive glutamine contribution to citrate (Figure 1b, d, f), and thus the α-ketoglutarate/citrate ratio (Figure 1c, d). This suggests that carbon entry into the TCA cycle via AcCoA, can affect the α-ketoglutarate/citrate ratio, and suggest this as one point of regulation.

If carbon entry into the TCA cycle via AcCoA regulates the α-ketoglutarate/citrate ratio and reductive glutamine contribution to citrate then replenishing the pyruvate-derived citrate pool by forcing carbon into the TCA cycle via AcCoA should decrease reductive glutamine utilization. Increased glucose concentrations cannot be used to increase the oxidative carbon entry into the TCA cycle. However, since glucose can be converted to lactate, supplementing the media with high concentrations of lactate can impair cytosolic NAD+ regeneration and promote increased carbon contribution via AcCoA into the TCA cycle. Addition of lactate to the culture media shifts the reaction direction of lactate dehydrogenase from net synthesis to net consumption of lactate to produce pyruvate18. Because pyruvate-to-lactate conversion is a major route of NAD+ regeneration from NADH, higher lactate levels increase cytosolic NADH levels preventing cytosolic NAD+ recovery and increase carbon contribution into the TCA cycle via AcCoA19 (Figure 2a). Moreover, lactate addition uncouples the use of glucose-derived carbon, since both lactate and glucose feed into the same pyruvate pool. Lactate supplementation in the control condition increased the AcCoA contribution to α-ketoglutarate (M+3 in α-ketoglutarate from U-13C glutamine (Supplementary Figure S2a)) and decreased the α-ketoglutarate/citrate ratio along with reductive glutamine contribution to citrate (Supplementary Figure S3a). We confirmed the increase in AcCoA contribution to α-ketoglutarate during lactate supplementation is a result of increased pyruvate entry by comparing M+3 in α-ketoglutarate from U-13C glutamine to M+2 in α-ketoglutarate from U-13C lactate and U-13C glucose. We found that the sum of the M+2 contributions from glucose and lactate matched the M+3 contribution from glutamine, showing that supplementation of lactate leads to a joint contribution of glucose and lactate to pyruvate and it’s entry into the AcCoA pool (Supplementary Figure S3b (left panel)). Subsequently, we applied lactate supplementation to conditions that induce reductive glutamine utilization and found that AcCoA contribution to α-ketoglutarate increased (Figure 2b), and the α-ketoglutarate/citrate ratio decreased along with reductive glutamine contribution to citrate (Figure 2c, d, Supplementary Data 1). We again confirmed using the rotenone + lactate condition that both glucose and lactate contribute to the AcCoA pool (Supplementary Figure S3b (right panel)). Notably, the effect seen following exposure to hypoxia, rotenone and metformin was much more pronounced than for antimycin a. This may be due to the fact that complex I inhibition can be circumvented using the glycerol phosphate shuttle to pass electrons to complex II, while a block in complex III cannot be bypassed20. Together, these data show that carbon conversion to citrate via AcCoA modulates the α-ketoglutarate/citrate ratio, which in turn might determine the reductive glutamine contribution to citrate.

Figure 2
Metabolic parameters modulate reductive carboxylation. (a) Lactate supplementation (25mmol/L) in the media prohibits glucose conversion to lactate and thus forces an increased glucose contribution to the TCA cycle. Flux and metabolite state in standard ...

To further test the hypothesis that the α-ketoglutarate/citrate ratio determines whether glutamine is converted oxidatively (via glutamine anaplerosis) or reductively (via reductive carboxylation), we reasoned that supplementing cells that have increased reductive glutamine usage with acetate (to directly replenish the citrate pool (Figure 3a)) or citrate should shift the ratio from reductive back to oxidative glutamine utilization. To test this possibility, we added acetate (25mmol/L) or citrate (0.3 mmol/L and 1.2mmol/L) to cells in the presence of metformin. In the presence of acetate we measured the α-ketoglutarate/citrate ratio and reductive glutamine contribution to citrate normalized to the total glutamine contribution to citrate with a U-13C glutamine tracer (Supplementary Figure S2a). This normalization was undertaken to prevent the unlikely possibility that addition of acetate will disturb metabolite pool size and thus lead to an overall decrease in glutamine contribution to the metabolites. Acetate decreased the α-ketoglutarate/citrate ratio and similarly reduced the normalized reductive glutamine contribution to citrate (Figure 3b,c). The addition of acetate also led to increased oxidative glutamine metabolism in the TCA cycle.(Figure 3d). Furthermore, we tested whether acetate supplementation to metformin treatment also decreases the reductive glutamine contribution to palmitate using 5-13C glutamine (Figure 3e, Supplementary Figure S4). In line with the citrate labeling data, we measured reduced 5-13C glutamine labeling in m+5 to m+8 palmitate when acetate is supplemented in the medium of metformin treated cells. This finding corroborates that the reductive conversion of glutamine is reduced when acetate is added. With citrate supplementation, we measured the ratio between oxidative and reductive glutamine utilization using a U-13C-glutamine tracer. Measuring the α-ketoglutarate/citrate ratio in this condition is not possible due to residual media citrate impeding accurate measurements of intracellular citrate levels. We determined the ratio of oxidative versus reductive glutamine utilization based on M+4 in fumarate, malate and aspartate (oxidative contribution) and M+3 in fumarate, malate and aspartate (reductive contribution) (Supplementary Figure S2c). We found that the ratio between oxidative and reductive glutamine utilization in the presence of metformin increased with increasing citrate concentrations (Figure 3f), further arguing that the switch from oxidative to reductive glutamine utilization is a function of the α-ketoglutarate/citrate ratio.

Figure 3
The α-ketoglutarate/citrate ratio determines reductive glutamine utilization. (a) Acetate is a third carbon source beside glucose and glutamine that fuels the citrate pool. (b) α-ketoglutarate/citrate ratio, and (c) reductive glutamine ...

To determine if glucose contribution to the TCA cycle and the α-ketoglutarate/citrate ratio determines oxidative versus reductive glutamine metabolism in another cell line, we measured glucose contribution to the TCA cycle along with the corresponding α-ketoglutarate/citrate ratios under nine different growth conditions in 143B osteosarcoma cells. Analysis of U-13C glucose and U-13C glutamine tracer data demonstrates that the levels of reductive glutamine contribution to citrate varied by 8 fold with treatments (Figure 4a; Supplementary Data 1). Addition of lactate, β-nicotinamide mononucleotide (NMN) (NAD+ precursor) and the mitochondrial uncoupling agent FCCP decreased reductive glutamine contribution, while addition of AICAR (a precursor of AMP) had only minor effects that were not statistically significant. Oligomycin (a direct inhibitor of mitochondrial ATP synthase), rotenone, metformin, and antimycin a all led to increased reductive glutamine contribution to citrate (Figure 4a). The AcCoA contribution to α-ketoglutarate, the total pyruvate contribution to citrate, citrate and α-ketoglutarate levels, as well as the α-ketoglutarate/citrate ratio were correlated with reductive glutamine contribution to citrate (Figure 4b–h). With the exception of lactate supplementation, total pyruvate contribution to citrate is given based on the total glucose contribution to citrate. In the case of lactate the total pyruvate contribution to citrate is resembled by the sum of the total glucose and lactate contribution to citrate. Notably, for some stress conditions (lactate, oligomycin, rotenone, and metformin) α-ketoglutarate instead of citrate is the major contributor to the change in the α-ketoglutarate/citrate ratio (Figure 4d). Nonetheless, the α–ketoglutarate/citrate ration, but not α-ketoglutarate or citrate levels themselves, correlate most strongly with the percent reductive glutamine contribution to citrate (figure 4g and h). This observation strongly argues that the ratio, rather than the α-ketoglutarate nor the citrate concentration themselves, is the major determinant of reductive glutamine utilization. Thus, it is unlikely that α–ketoglutarate (or isocitrate) concentrations per se regulates isocitrate dehydrogenase on the enzyme level.

Figure 4
Reductively derived citrate correlates with metabolic parameters in 143B cells. (a) Reductive glutamine contribution to citrate. (b) AcCoA contribution to α-ketoglutarate. (c) Total pyruvate contribution to citrate. (d) Alterations in citrate ...

To expand our findings and exclude the possibility that the effects we observed could all be accounted for by an increase in α-ketoglutarate-to-citrate carbon exchange or be compromised by labeled CO2 fixation, we measured the reductive glutamine contribution to the fatty acid palmitate in the PC3 prostate adenocarcinoma cell line (Figure 5; Supplementary Data 1). Reductive glutamine contribution to palmitate was measured using a 5-13C-glutamine tracer, which reaches palmitate only through reductive glutamine metabolism (Supplementary Figure S4). The contribution of this tracer to palmitate was calculated based on an isotopic spectral analysis model21, 22. The 9 conditions tested spanned a 14-fold range of reductive glutamine contribution to palmitate (Figure 5). Similar to the results obtained with citrate labeling in A549 and 143B cells, reductive glutamine contribution to palmitate correlated with AcCoA contribution to α-ketoglutarate, the total glucose contribution to citrate, and the α-ketoglutarate/citrate ratio (Figure 5). These results further corroborate the hypothesis that the above mentioned criteria determine the extent of reductive glutamine metabolism across a wide range of cellular conditions.

Figure 5
Reductively derived fatty acids correlates with metabolic parameters in PC3 cells. Correlation between the reductive glutamine contribution to fatty acids (palmitate) and (a) the AcCoA contribution to α-ketoglutarate, (b) the total glucose contribution ...

To further elucidate that an increase in reductive glutamine contribution to citrate results in a net flux increase such as it has been shown previously for hypoxia5, we measured the net reductive glutamine flux to palmitate in the presence of antimycin a, oligomycin or TTFA (Supplementary Figure S5). In accordance with results observed under hypoxia, we found that net reductive glutamine flux to palmitate increased in the presence of antimycin a, oligomycin or TTFA by approximately six-, five and threefold, respectively (Supplementary Figure S5). This data suggests that, at least in certain conditions, this major switch in carbon fueling results also in a net flux increase.

Multiple upstream events influence TCA cycle carbon entry

To investigate if there is a sole signaling event that controls carbon entry into the TCA cycle via AcCoA, we further tested how reductive glutamine contribution to citrate is regulated under hypoxia and in the presence of complex I/III inhibitors (rotenone, metformin and antimycin a). It has been shown previously that inhibition of PDK1 with DCA reduces the contribution of reductive glutamine carboxylation in hypoxia5. To evaluate the extent by which PDKs impact reductive glutamine utilization, we determined the effect of the PDK inhibitor dichloroacetate (DCA)23, 24 on the reductive glutamine contribution to citrate in the presence of rotenone, metformin or antimycin a. The dose of DCA was adjusted to a concentration that significantly reduced PDHE1a Ser232 phosphorylation in hypoxia (Supplementary Figure S6). The concentration of 5mmol/L DCA that met these criteria matches the concentration used previously5. Our data corroborated that PDK inhibition by DCA significantly reduced reductive glutamine contribution to citrate in hypoxia (Figure 6a) 5, but DCA did not alter reductive carboxylation in the presence of complex I/III inhibitors (Figure 6a) suggesting that these stresses may utilize distinct mechanisms.

Figure 6
PDK1 regulates carbon entry into the TCA cycle in hypoxia. (a) Reductive glutamine contribution to citrate for different stress conditions with and without the pyruvate dehydrogenase kinase (PDK) inhibitor DCA. (b) NAD+/NADH ratio for different stress ...

One consequence of respiratory chain inhibition is decreased mitochondrial conversion of NADH to NAD+ and thus a reduced mitochondrial NAD+/NADH ratio6, 25. Interestingly, the pyruvate dehydrogenase reaction is coupled to this cofactor ratio17; therefore it is possible that changes in the mitochondrial NAD+/NADH ratio following complex I/III inhibition are responsible for reduced carbon entry into the TCA cycle via AcCoA. To test this hypothesis, we measured the NAD+/NADH ratio using HPLC (Supplementary Figure S8), in cells growing in standard culture conditions and under the four stress conditions. We confirmed literature data that, indeed, the NAD+/NADH ratio decreased by more than tenfold in the presence of complex I/III inhibitors compared to the control (Figure 6b); however, there was no significant alteration of the NAD+/NADH ratio under hypoxia (Figure 6b). We further estimated from the lactate to pyruvate ratio the amount of free NAD+/NADH in the cytosol. As expected, the cytosolic lactate to pyruvate ratio26 increased following rotenone, metformin and antimycin a treatment (Supplementary Figure S9) suggesting that the total decrease in NAD+/NADH measured likely occurs mainly in the mitochondria. Thus this ratio could mediate the directionality of glutamine metabolism in the presence of respiratory inhibitors.

To test if the lower NAD+/NADH ratio limits carbon entry into the TCA cycle during respiratory chain inhibition and to exclude a bias due to the fact that we can directly measure only total but not free NAD+/NADH, we supplemented the media with the NAD+ precursor NMN. Supplementation of cells with NMN increases the free NAD+ level27, thus increasing the NAD+/NADH ratio (Figure 7a). As expected from literature data, NMN addition increased the NAD+/NADH ratio in the presence of metformin by more than fivefold compared to metformin alone (Figure 7b). Moreover, the AcCoA contribution to α-ketoglutarate increased when NMN was added to metformin-treated cells, while the reductive glutamine contribution decreased (Figure 7c,d). These data suggest that changes in the NAD+/NADH ratio elicited by respiratory inhibitors changes the α-ketoglutarate/citrate ratio, which in turn, shifts glutamine utilization from oxidative to reductive.

Figure 7
NAD+/NADH ratio limits carbon entry into the TCA cycle. (a) NMN supplementation (25mmol/L) increased NAD+ level and thus increased NAD+/NADH ratio, which leads to increased glucose flux through pyruvate dehydrogenase. Flux and metabolite state in standard ...

While the above data suggest that the NAD+/NADH ratio affects the pyruvate dehydrogenase reaction, it is unclear if this happens directly via cofactor coupling or indirectly via effects on pyruvate dehydrogenase kinase isoform 4 (PDK4) activity. Thus we tested if PDK4 is expressed differently in hypoxia compared to the complex I/III inhibitors (Supplementary Figure S3c). We found that PDK4 expression increased by approximately threefold during metformin treatment compared to hypoxia. PDK4-mediated phosphorylation inhibits pyruvate dehydrogenase activity and PDK4 is known to be strongly regulated by the NAD+/NADH ratio28. If the pyruvate dehydrogenase complex is directly inhibited by the NAD+/NADH ratio via cofactor coupling, instead of PDK4-mediated phosphorylation, addition of NMN in the presence of DCA (which inhibits PDK428) and metformin should still increase the AcCoA contribution to α-ketoglutarate (Figure 7a). Thus, we added DCA at concentrations determined to block PDHE1a phosphorylation (Supplementary Figure S6), and found that NMN increased AcCoA contribution to α-ketoglutarate and as expected, decreased reductive glutamine contribution to citrate in the presence of metformin plus DCA, excluding the involvement of PDK4 (Figure 7e–f). While the NAD+/NADH ratio can control carbon entry into the TCA cycle, and thus reductive carboxylation, other regulatory events resulting from complex I/III inhibition cannot be excluded. These data suggest that while alterations in PDH activity via phosphorylation can promote reductive carboxylation, this is not the only mechanism active under all conditions.


Reductive glutamine contribution to metabolites and biomass building blocks was recently identified as a phenomenon to support growth of hypoxic and respiratory chain impaired cells5, 6, 7, 8. We demonstrate here a general mechanistic explanation for how metabolic rearrangements enable reductive glutamine contribution to citrate (Figure 8). Although our approach is limited in looking at cell metabolite levels without information about compartmentalization of pathways, with the consequence that we cannot provide thermodynamic calculations, we identified the α-ketoglutarate/citrate ratio itself as a critical determinant of reductive glutamine utilization. In some cases, this may not represent a true increase in net flux, but a relative flux change with increased exchange may also be involved as both lead to increased 5-carbon labeled citrate from glutamine. Nevertheless, altered α-ketoglutarate/citrate ratios can promote increased net reductive glutamine flux under some conditions including hypoxia5 or treatment with antimycin a, oligomycin or TTFA.

Figure 8
Reductive glutamine carboxylation is a function of the α-ketoglutarate to citrate ratio. In standard growth conditions proliferation relevant fatty acids are produced mainly from glucose (left). Any stress condition leading to an increased α-ketoglutarate ...

A wide range of conditions influence the α-ketoglutarate/citrate ratio by modulating carbon entry into the TCA cycle via AcCoA. Moreover, our data demonstrate that other events (e.g. acetate or citrate supplementation) that alter the α-ketoglutarate/citrate ratio will play a role in determining whether glutamine is metabolized oxidatively or reductively. Regarding the carbon entry into the TCA cycle via AcCoA, there are at least two upstream mechanisms explaining how carbon entry (and subsequent downstream metabolic changes) are regulated. In the case of hypoxia, decreased carbon entry into the TCA cycle is driven at least in part by PDK1-mediated inhibition of pyruvate dehydrogenase, while complex I/III inhibition decreases carbon entry into the TCA cycle through a decrease in the NAD+/NADH ratio. The latter is the result of mitochondrial electron transport inhibition, which in turn decreases pyruvate to AcCoA conversion likely via cofactor coupling. By extension, any condition that affects the α-ketoglutarate/citrate ratio, regardless of the upstream regulation that initiates this change, is predicted to alter reductive versus oxidative glutamine utilization and consequently the fueling source for proliferation relevant fatty acid synthesis. Although our approach has the limitation that we cannot conclude whether reductive carboxylation takes place in the mitochondria or the cytosol, this mechanistic understanding allows for the first time predictions of environmental and genetic conditions, which promote reductive glutamine utilization and might lead to the development of drugs inhibiting this process.

Although reductive carboxylation has mainly been investigated in cancer cells there is evidence that at least some non-transformed cell also use this pathway (e.g. non-transformed cells from brown fat (differentiated brown adipocytes22), lung (MRC55), prostate (p69, unpublished data by S-M Fendt), and normal lymphocytes5 Hence, this mode of regulation may allow carbon metabolism to rapidly adapt to changing growth conditions. In this way, the cell can immediately switch carbon source utilization without involving complex transcriptional or allosteric regulation and ensure optimal substrate usage to support growth under various conditions. Furthermore, this mechanism is a consequence of any upstream event altering α-ketoglutarate and/or citrate levels and requires no further energy investment. Yet, to which extent NAD(P)+/NAD(P)H levels, which are cofactors coupled to the α-ketoglutarate to citrate ratio and affect the activity of enzymes such as glutamate dehydrogenase, influence the reaction direction remains to be determined, but some influence is likely based on kinetic considerations. As a result, targeting reductive glutamine metabolism for therapeutic benefit may require an approach that impacts intrinsic properties of the metabolic network, rather than interruption of signaling events that indirectly influence the process.


Cell lines and cell culture conditions

All cell lines were obtained from ATCC. All experiments were performed in DMEM (Mediatech) with 10% dialyzed fetal bovine serum (Invitrogen) and 1% pen/strep (Mediatech) and glucose or glutamine with either U-13C glucose (CLM-1396 Cambridge Isotopes), U-13C glutamine (605166 Sigma) or 5-13C glutamine (CLM-1166 Cambridge Isotopes). Cell lines were treated for 1day or in case of fatty acid labeling for 3 days. Growth conditions were altered in the following ways: AICAR 0.25 mmol/L (143B), antimycin 2 μg/ml (PC3) and 20ng/ml (A549, 143B), citrate 0.3 and 1.2 mmol/L (A549), DCA 5mmol/L (A549, PC3), FCCP 10 μmol/L (PC3) and 2.5 μmol/L (143B), hypoxia 1 % (A549, 143B, PC3), lactate 25 mmol/L (A549, 143B), metformin 1 mmol/L (A549, 143B), myxothiazol 1 μmol/L (PC3), NMN 25mmol/L (A549, 143B), oligomycin 5 μmol/L (PC3) and 2.5 μmol/L (143B), rotenone 1 μg/ml (PC3) and 10 ng/ml (A549, 143B), TTFA 400 μmol/L (PC3). All compounds were obtained from Sigma.

Oxygen consumption

Oxygen consumption was measured with an Oxytherm instrument (Hansatech). Cells were trypsinized and resuspended in fresh media. Oxygen consumption of detached cells was measured for 10min. The slope of the linear range was used to calculate rates. Error bars are from biological replicates.

Carbon contribution to TCA cycle and palmitate

To asses metabolite levels and metabolite labeling we applied the methods described in Metallo et al5. In brief labeled tissue cultures were washed with saline and metabolism was quenched with −20°C cold 65% methanol. After cell scraping in 65% methanol, −20°C cold chloroform was added and the samples were vortexed at 4°C to extract metabolites. Phase separation was achieved by centrifugation at 4°C. Methanol phase (polar metabolites) and chloroform phase (fatty acids) were separated and dried applying constant air flow. Dried metabolite samples were stored at −80°C.

Polar metabolite samples were derivatized with methoxyamine (TS-45950 Thermo Scientific) for 90min at 40°C and subsequently with N-(tert-butyldimethylsilyl)-N-methyl-trifluoroacetamide, with 1% tert-Butyldimethylchlorosilane (375934 Sigma) for 60min at 60°C. Fatty acids were esterified with sulfuric acid/methanol for 120min at 60°C and subsequently extracted with hexane. Isotopomer distributions of polar metabolites and fatty acids were measured with a 6890N GC system (Agilent Technologies) combined with a 5975B Inert XL MS system (Agilent Technologies). One microliter of samples was injected in splitless mode with an inlet temperature of 270 °C onto a DB35MS column. The carrier gas was helium with a flow rate of 1ml/min. For the measurement of polar metabolites the oven was held at 100°C for 3 minutes and then ramped to 300°C with a gradient of 2.5°C/min. For fatty acid samples the oven was held at 80°C for 1 min and ramped with 5°C/min to 300°C. The MS system was operated under electron impact ionization at 70eV. A mass range of 100–650amu was scanned.

Isotopomer distributions were extracted from the raw ion chromatograms using a custom Matlab M-file, which applies consistent integration bounds and baseline correction to each ion29. Additionally we corrected for naturally occurring isotopes using the method of Fernandez et al30. Total contribution of carbon was calculated using the following equation 31:


Here n is the number of C atoms in the metabolite, i the different mass isotopomers and m the abundance of a certain mass. In the case of lactate supplement, total pyruvate contribution instead of total glucose contribution is depicted and M+3 of α-ketoglutarate from U-13C glutamine was used as a measure for AcCoA contribution to α-ketoglutarate. For relative metabolite levels the total ion count was normalized to the internal standard norvaline and to cell number counted with an automated cell counter (Nexcelom). Isotopomer distributions of fatty acids were further fitted to an isotopic spectral analysis model previously described5. Isotopic spectral analysis is a nonlinear regression method for fitting the gas chromatography - mass spectrometry data to a model for biosynthesis with two unknowns, D, the fractional contribution of the labeled precursor to the biosynthetic precursor pool, and g(t), the fraction of newly synthesized product present at time t. 21, 22.

During citrate supplementation we specifically focus on the ratio between oxidative and reductive glutamine conversion because absolute contributions cannot be inferred due to variations in the label dilution at different amounts of supplementation. Moreover, high concentrations of unlabeled and residual citrate from the media prevented the accurate measurement of label in this pool, hence the ratio of oxidative versus reductive glutamine utilization was determined from the measurement of M+4 in fumarate, malate and aspartate (oxidative contribution) and M+3 in fumarate, malate and aspartate (reductive contribution) (Supplementary Figure S2c).

Net reductive glutamine fluxes to palmitate in the presence or absence of antimycine, oligomycine or TTFA were calculated as described by Metallo et al.5 based on the fractional contribution of reductively utilized glutamine and the fraction of newly synthesized glutamine (D and g(t) from the isotopic spectral analysis model) combined with cell numbers and growth rates5.

Raw data are depicted in Supplementary Data 1. Error bars are from biological replicates. We verified for our data set that glutaminolysis, protein turnover and CO2 refixation can be neglected. This is necessary because glutamiolysis can occur in mammalian cells32 and CO2 refixation has been shown to be important in microbes33. Therefore, we analyzed M+0 from pyruvate on a U-13C glutamine tracer (significantly altered M+0 indicates glutaminolysis), M+5 of glutamine from a U-13C glutamine tracer (significantly altered M+5 indicates protein turnover) and M+1 and M+2 from a 1-13C glutamine tracer (M+2 indicates CO2 refixation) (Supplementary Figure S7). In accordance with previous reports5, 34, 35 we found that, glutaminolysis, protein turnover and CO2 refixation can be neglected.

NAD+/NADH ratio

The protocol used to extract NAD+/NADH from cells was adapted from a previously described method36. In brief tissue culture cells were washed with ice cold phosphate buffered saline and immediately quenched with liquid nitrogen. −20 °C cold extraction solution (40% methanol, 40% acetonitrile, 20% buffer) was added and plates were incubated at −20 °C for 15 minutes. Cells were scraped on dry ice and centrifuged at 4 °C. The supernatant was collected and the remaining pellet re-extracted twice with extraction solution. The supernatant was dried and analyzed by high pressure liquid chromatography. The quenching protocol was validated by measuring the ATP, ADP and AMP with liquid chromatography – mass spectrometry. The calculated energy charge was 0.73.

Dried extracts were dissolved in water and separation of compounds was achieved by HPLC using an Agilent (C8) 2.6 × 250 mm, 5 μmol/L particle column (Agilent Technologies). The HPLC method was adapted from a published method37 and verified. Mobile phase flow rate was 1mL/min. Eluent A (50 mmol/L potassium phosphate dibasic and 8 mmol/L tetrabutylammonium bisulfate aqueous adjusted to pH 5.8) and eluent B (50 mmol/L potassium phosphate dibasic and 8 mmol/L tetrabutylammonium bisulfate aqueous solution adjusted to pH 5.8 with 40 % acetonitrile) were applied with a time dependent gradient. Absorbance of NAD was detected at 254 nm wavelength and NADH was detected at 254 nm and 340 nm. The method was verified with calibration curves, which are depicted in Supplementary Figure S8. Error bars are from biological replicates.

Western Blot

PDH and phospo-PDH antibodies were obtained from Invitrogen or Calbiochem, respectivly and diluted to 1μg/ml or 0.25μg/ml, respectively.


Error bars depict standard deviation. R and p values for the depicted correlations were calculated with the Matlab integrated function corrcoef: [R,P]=corrcoef returns P, a matrix of p-values for testing the hypothesis of no correlation. Each p-value is the probability of getting a correlation as large as the observed value by random chance, when the true correlation is zero. P values were also calculated for bar graphs using a student’s T-test (two-tailed, unequal variance) to determine whether two samples are likely to have come from the same two underlying populations that have the same mean.

Supplementary Material


SMF is supported by the German Research Foundation (DFG), grant FE1185. ELB is supported by NRSA postdoctoral fellowship F32 CA132358. MGVH acknowledges NIH grant 5-P30-CA14051-39 and support from the Damon Runyon Cancer Research Foundation, the Burrough’s Wellcome Fund, and the Smith Family. We also acknowledge NIH grant - 1R01CA160458-01A1 to GS.


Competing Financial Interests

The authors declare no competing financial interests.

Authors Contribution

SMF conceived and designed the study, performed experiments, measured mass distributions and metabolite levels, analyzed all data and drafted the manuscript. ELB helped conceiving the study and helped drafting the manuscript. MAK performed oxygen consumption measurements and helped with metabolite level quantification and labeling experiments. BAO performed western blot analysis. JRM performed NAD+/NADH measurements and helped with metabolite level quantification. TMW measured ATP, ADP and AMP and NIV helped with NAD+/NADH measurements. LG provided support and reagents. MGVH and GS provided conceptual advice and helped drafting the manuscript. All authors read and approved the final manuscript.


1. Lunt SY, Vander Heiden MG. Aerobic Glycolysis: Meeting the Metabolic Requirements of Cell Proliferation. Annu Rev Cell Dev Biol. 2011;27:441–464. [PubMed]
2. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–1033. [PMC free article] [PubMed]
3. Ward Patrick S, Thompson Craig B. Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate. Cancer Cell. 2012;21:297–308. [PMC free article] [PubMed]
4. Daye D, Wellen KE. Metabolic reprogramming in cancer: Unraveling the role of glutamine in tumorigenesis. Semin Cell Dev Biol. 2012;23(4):362–369. [PubMed]
5. Metallo CM, Gameiro Pa, Bell EL, Mattaini KR, Yang J, Hiller K, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2011;481:380–384. [PMC free article] [PubMed]
6. Mullen AR, Wheaton WW, Jin ES, Chen P-H, Sullivan LB, Cheng T, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature. 2011;481(7381):385–388. [PMC free article] [PubMed]
7. Wise DR, Ward PS, Shay JES, Cross JR, Gruber JJ, Sachdeva UM, et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. PNAS. 2011;108:19611–19616. [PubMed]
8. Filipp FV, Scott Da, Ronai Zea, Osterman AL, Smith JW. Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells. Pigm Cell Res. 2012;25(3):375–383. [PMC free article] [PubMed]
9. Keith B, Johnson RS, Simon MC. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2012;12:9–22. [PMC free article] [PubMed]
10. Kaelin WG. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer. 2008;8:865–873. [PubMed]
11. Kim J-W, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006;3:177–185. [PubMed]
12. Papandreou I, Cairns Ra, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 2006;3:187–197. [PubMed]
13. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010;35:427–433. [PMC free article] [PubMed]
14. DeBerardinis RJ, Cheng T. Q’s next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene. 2010;29:313–324. [PMC free article] [PubMed]
15. Dickman SR. The Enzymes (chapter aconitase) Academic Press; New York: 1961.
16. Sauer U. Metabolic networks in motion: 13C-based flux analysis. Mol Syst Biol. 2006;2:62. [PMC free article] [PubMed]
17. Duarte NC, Becker Sa, Jamshidi N, Thiele I, Mo ML, Vo TD, et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data. PNAS. 2007;104:1777–1782. [PubMed]
18. Huckabee WE. Control of Concentration Gradients of Pyruvate and Lactate Across Cell Membranes in Blood. J Appl Physiol. 1956;9:163–170. [PubMed]
19. Mintun Ma, Vlassenko AG, Rundle MM, Raichle ME. Increased lactate/pyruvate ratio augments blood flow in physiologically activated human brain. PNAS. 2004;101:659–664. [PubMed]
20. Voet D, Voet JG. Biochemistry. John Wiley & Sons; 2004.
21. Kharroubi AT, Masterson TM, Aldaghlas TA, Kennedy KA, Kelleher JK. Isotopomer spectral analysis of triglyceride fatty acid synthesis in 3T3-L1 cells. Am J Physiol. 1992;263:E667–675. [PubMed]
22. Yoo H, Antoniewicz MR, Stephanopoulos G, Kelleher JK. Quantifying reductive carboxylation flux of glutamine to lipid in a brown adipocyte cell line. JBC. 2008;283:20621–20627. [PMC free article] [PubMed]
23. Bersina RM, Stacpoole PW. Dichloroacetate as metabolic therapy for myocardial ischemia and failure. Am Heart J. 1996;134(5):841–855. [PubMed]
24. Whitehouse S, Cooper RH, Randle PJ. Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids. Biochem J. 1974;141:761–774. [PubMed]
25. Gao Q, Wolin MS. Effects of hypoxia on relationships between cytosolic and mitochondrial NAD(P)H redox and superoxide generation in coronary arterial smooth muscle. Am J Physiol Heart Circ Physiol 295. 2008;295:978–989. [PubMed]
26. Veech RL. Mini-Series: Paths to Discovery The Determination of the Redox States and Phosphorylation Potential in Living Tissues and Their Relationship to Metabolic Control of Disease Phenotypes. Biochem Mol Biol Educ. 2006;34:168–179. [PubMed]
27. Yoshino J, Mills KF, Yoon MJ, Imai S-i. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011;14:528–536. [PMC free article] [PubMed]
28. Bowker-Kinley MM, Davis WI, Wu P, Harris RA, Popov KM. Evidence for existence of tissue-specific regulation of mammalian pyruvate dehydrogenase complex. Biochem J. 1998;329:191–196. [PubMed]
29. Antoniewicz MR, Kelleher JK, Stephanopoulos G. Elementary metabolite units (EMU): a novel framework for modeling isotopic distributions. Metab Eng. 2007;9:68–86. [PMC free article] [PubMed]
30. Fernandez CA, Des Rosiers C, Previs SF, David F, Brunengraber H. Correction of 13C mass isotopomer distributions for natural stable isotope abundances. J Mass Spectrom. 1996;31:255–262. [PubMed]
31. Nanchen A, Fuhrer T, Sauer U. Determination of metabolic flux ratios from 13C-experiments and gas chromatography-mass spectrometry data: protocol and principles. Methods Mol Biol. 2007;358:177–197. [PubMed]
32. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol. 2005;15(4):300–308. [PubMed]
33. Leighty RW, Antoniewicz MR. Parallel labeling experiments with [U-13C]glucose validate E. coli metabolic network model for 13C metabolic flux analysis. Metab Eng. 2012;14(5):533–541. [PubMed]
34. Gaglio D, Metallo CM, Gameiro Pa, Hiller K, Danna LS, Balestrieri C, et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol. 2011;7:523. [PMC free article] [PubMed]
35. Grassian AR, Metallo CM, Coloff JL, Stephanopoulos G, Brugge JS. Erk regulation of pyruvate dehydrogenase flux through PDK4 modulates cell proliferation. Genes Dev. 2011;25:1716–1733. [PubMed]
36. Rabinowitz JD, Kimball E. Acidic acetonitrile for cellular metabolome extraction from Escherichia coli. Anal Chem. 2007;79:6167–6173. [PubMed]
37. Zhang DX, Zou A-p, Li P-L. Coronary Small Arteries through Apyrase- and 5′-Nucleotidase-Mediated Metabolism. J Vasc Res. 2001;38:64–72. [PubMed]